The Efficacy of Intralesional Injection of Glucantime with Mesotherapy for the Treatment of Cutanuos Leishmaniasis in Comparison to Classic Method

Document Type : Original Article(s)

Authors

1 Assistant Professor, Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

2 Medical Student, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Cutaneuos leishmaniasis is a common parasitic disease in 88 countries. Iran is one of the hyperendemic regions of cutaneuos lieshmaniasis. Mesotherapy is a technique used to deliver medication to a specific area of the body to treat a specific condition. This is done by painless multiple intradermal microinjections.Methods: In this clinical trial study, 90 patients with confirmed cutaneuos lieshmaniasis in Isfahan Lieshmaniasis Research Center, were selected and randomly divided into 2 groups. Group A and B were treated by classic intralesional and mesotherapy injection respectively; intralesional injection of glucantime once a week for a maximum of 6 weeks was done for both groups. Patients were followed one week, one month and 3 months after the treatment. P value < 0.05 was considered as significant level.Results: Sixty patients completed the study. There was no significant difference between the mean of changes of disease indecies of the lesions (size of ulcer, erythema and induration) in classic group and mesotherapy group. The speed of the lesion-cure regarding cure of ulcer, erythema and induration in the mesotherapy group was significantly less than classic group. The mean value of pain severity and the mean volume of the drug needed for each centimeter of the lesions in Mesotherapy group was significantly less than classic group. The results showed no statistical significant difference between the clinical and parasitological cure rate of the two groups.Conclusion: Intralesional injection of glucantime by mesutherapy was more rapid, painless and cost effective than the classic method. This could promote the compliance of patients in the treatments procedure.

Keywords

References

  1. Berman JD. Human leishmaniasis: clinical, diagnostic and chemotherapeutic in the last to years. Clin Infect Dis 1997; 24(4): 684-703.
  2. Hepburn NC. Cutaneuos leishmaniasis: an overview. J Postgrad Med 2003; 49(1): 50-4.
  3. Enk CD, Gardlo K, Hochberg M, Ingber A, Ruzicka T. Cutaneuos leishmaniasis. Hautarzt 2003; 54(6): 506-12. [In German].
  4. Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007; 5(3): 150-8.
  5. Herpburn NC. Cutaneuos leishmaniasis. Clin Exp Dermatol 2000; 25(5): 363-70.
  6. Olliaro PL, Guerin PJ, Gerstls S, Hasskojold AA, Rottingen JA, Suder S. Treatment options for visceral leishmaniasis. System review of clinical studies done in India, 1980-2004. Lancet Inf Dis 2005; 5(12): 763-74.
  7. Harry L, Arnold JR. Parasitic infestations, stingi and bites. In: Odom RB, James WD, Berger TG. Andrew's Diseases of the Skin: Clinical Dermatology. 9th ed. Philadelphia: WB Saunders 1990; p. 488.
  8. Nilforoushzadeh MA, Jaffary F, Moradi S, Derakhshan R, Haftbaradaran E. Effect of topical honey application along with intralesional injection of glucantiome in the treatment of cutaneuos leishmaniasis. BMC Complement Altern Med 2007; 7: 13-6.
  9. Faris RM, Jarallah JS, Khoja TA, al-Yamani MJ. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993; 32(8): 610-2.
  10. Kellum RE. Treatment of cutaneous leishma-niasis with an intralesional antimonial drug (Pentostam). J Am Acad Dermatol 1986; 15(4 Pt 1): 620-2.
  11. Flaig MJ, Rupec J, Ruzickat, Rupec RA. Topical treatment of persistant cutaneuos leishmaniasis with paromomycin. Hautarzt 2007; 58(8): 689-90, 692.
  12. Rohrich RJ. Mesotherapy: what is it? Does it work? Plast Reconstr Surg 2005; 115(5): 1425.
  13. Vodamurthy M. Mesotherapy. Indian J Dermatol Venereol Leprol 2007; 73(1): 60-2.
  14. Matarasso A, Pfeifer TM; Plastic Surgery Educational Foundation DATA Committee. Mesotherapy for body contouring. Plast Reconstr Surg 2005; 115(5): 1420-4.
  15. Ardehali S, Rezaee HR, Nadim A. Leishmania and Leishmaniasis Tehran. Tehran: Center for Academic Publication; 1985. p. 10-80.
  16. Desjeux P. The increase in risk factors of leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95(3): 239-43.
  17. Asilian A, Sadegninia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol 2004; 43(4): 281-3.
  18. Moosavi Z, Nakhli A, Rassaii S. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Int J Dermatol 2004; 44 (12): 1064-5.
  19. Faghihi G, Tavakoli-kia R. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin Exp Dermatol 2003; 28(1): 13-6.
Journal of Isfahan Medical School
Volume 28, Issue 114 - Serial Number 114
September and October 2011
Pages 870-878

Files

History

  • Receive Date: 03 March 2011
  • Revise Date: 27 May 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics